相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial
Henrik Gudbergsen et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2021)
GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis
Karan R. Chadda et al.
OBESITY REVIEWS (2021)
Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Jingxin Li et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis
Lin Xia et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
Ian J. Neeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis
Ioannis Avgerinos et al.
DIABETES OBESITY & METABOLISM (2020)
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
W. Timothy Garvey et al.
DIABETES CARE (2020)
Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss
Husam Ghanim et al.
DIABETES OBESITY & METABOLISM (2020)
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
Jessica A. Huthmacher et al.
DIABETES CARE (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Bernard Zinman et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Diabetes Mellitus and Cardiovascular Disease Emerging Therapeutic Approaches
Ann Marie Schmidt
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
Huub J. van Eyk et al.
CARDIOVASCULAR DIABETOLOGY (2019)
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al.
DIABETES CARE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman et al.
DIABETES CARE (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Charlotte Granhall et al.
CLINICAL PHARMACOKINETICS (2019)
Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Michael A. Nauck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis
Panagiotis Andreadis et al.
DIABETES OBESITY & METABOLISM (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Progress and challenges in anti-obesity pharmacotherapy
Daniel H. Bessesen et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial
Signe Frossing et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
Pelle L. Ishoy et al.
DIABETES OBESITY & METABOLISM (2017)
Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
P. Mensberg et al.
DIABETES OBESITY & METABOLISM (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Thomas C. Marbury et al.
CLINICAL PHARMACOKINETICS (2017)
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
Jeanne S. Geiser et al.
CLINICAL PHARMACOKINETICS (2016)
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment ( LIRA-RENAL): A Randomized Clinical Trial
Melanie J. Davies et al.
DIABETES CARE (2016)
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Michael A. Nauck et al.
DIABETOLOGIA (2016)
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks
Nitesh D. Kuhadiya et al.
DIABETES CARE (2016)
Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment
G. E. Umpierrez et al.
DIABETES OBESITY & METABOLISM (2016)
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
A. Blackman et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Thomas Fremming Dejgaard et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
T. Karagiannis et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
A. Ahmann et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial
Ravi Retnakaran et al.
DIABETES CARE (2014)
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Anna Secher et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Glucagon-like peptide-1 receptor agonist and basal insulin combination tre atment for the management of type 2 diabetes: a systematic review and meta-analysis
Conrad Eng et al.
LANCET (2014)
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
M. J. Armstrong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
Sun H. Kim et al.
DIABETES CARE (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Matteo Monami et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Jessica E. Matthews et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
分享论文
